Current status of pharmacogenomics testing for anti-tumor drug therapies : approaches to non-melanoma skin cancer

Grealy, Rebecca & Griffiths, Lyn R. (2009) Current status of pharmacogenomics testing for anti-tumor drug therapies : approaches to non-melanoma skin cancer. Molecular Diagnosis and Therapy, 13(2), pp. 65-72.

View at publisher

Abstract

Skin cancer is one of the most commonly occurring cancer types, with substantial social, physical, and financial burdens on both individuals and societies. Although the role of UV light in initiating skin cancer development has been well characterized, genetic studies continue to show that predisposing factors can influence an individual's susceptibility to skin cancer and response to treatment. In the future, it is hoped that genetic profiles, comprising a number of genetic markers collectively involved in skin cancer susceptibility and response to treatment or prognosis, will aid in more accurately informing practitioners' choices of treatment. Individualized treatment based on these profiles has the potential to increase the efficacy of treatments, saving both time and money for the patient by avoiding the need for extensive or repeated treatment. Increased treatment responses may in turn prevent recurrence of skin cancers, reducing the burden of this disease on society. Currently existing pharmacogenomic tests, such as those that assess variation in the metabolism of the anticancer drug fluorouracil, have the potential to reduce the toxic effects of anti-tumor drugs used in the treatment of non-melanoma skin cancer (NMSC) by determining individualized appropriate dosage. If the savings generated by reducing adverse events negate the costs of developing these tests, pharmacogenomic testing may increasingly inform personalized NMSC treatment.

Impact and interest:

1 citations in Scopus
Search Google Scholar™
2 citations in Web of Science®

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 63007
Item Type: Journal Article
Refereed: No
Keywords: cetuximab, epidermal growth factor receptor kinase inhibitor, erlotinib, fluorouracil, gefitinib, retinoid, cancer recurrence, cancer surgery, cancer susceptibility, chemosurgery, gastrointestinal symptom, gene overexpression, hematologic disease, human, neurological complication, non melanoma skin cancer, pharmacogenomics, priority journal, prognosis, protein expression, review, single nucleotide polymorphism, skin cancer, treatment response, Antineoplastic Agents, Cell Proliferation, Fluorouracil, Humans, Pharmacogenetics, Receptor, Epidermal Growth Factor, Skin Neoplasms
DOI: 10.1007/BF03256316
ISSN: 1177-1062
Divisions: Current > Institutes > Institute of Health and Biomedical Innovation
Copyright Owner: Copyright 2009 Adis International Ltd.
Deposited On: 27 Sep 2013 06:22
Last Modified: 25 Oct 2016 23:41

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page